Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected

This article was originally published in PharmAsia News

Executive Summary

Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.

Advertisement

Related Content

Waiting For Blockbusters: Osteoporosis Market Burdened With Black Box Warnings, Reimbursement Woes, And Spare Pipelines
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)
After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel